NWR Communications’ Post

Molecular classification of DLBCL Solid table for lymphoma geeks such as myself https://lnkd.in/dmKmDrBE

For years Glyphosate in Roundup made yards beautiful.  In 2019, analysis from UW found exposure increased the risk of non-Hodgkin Lymphoma (NHL) by 41%. If you have been diagnosed and used Roundup regularly, call us at 844-888-HELP or visit https://lnkd.in/efpRQNPr for compensation eligibility information. #roundup #roundupcancer #non-hodgkinlymphoma #roundupvictimcompensation #faircompensation

Ravi Vij in Discussion with Dr. David Russler-Germain MD, on ASH 2023 Lymphoma https://lnkd.in/gKPcC-fU Get full access tro this video by joining us at https://lnkd.in/dDV7SUE3 #lymphoma #lymphomaawareness

First allogeneic dual CAR-T shows promise in B-cell Non-Hodgkin lymphoma. Cellectis presented encouraging data on UCART20x22, a groundbreaking allogeneic dual CAR T-cell product designed to target two well-established antigens. https://lnkd.in/gnPDrgEh

Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study https://lnkd.in/e9mxHeNB

Dr. Jeffrey Bryan is a textbook of knowledge when it comes to lymphoma! In our conversation, he offered a great deal of clarification around diagnostics and some of the newer treatement options for our lymphoma patients as well as the importance of general support for their overall health. Tune in to learn more! 🎙️ https://lnkd.in/euTXZt2i

Classic, ALK-DUSp22-, TP63- primary cutaneous anaplastic large cell lymphoma https://lnkd.in/dprhVkWp

Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment https://lnkd.in/dprhVkWp

Today we published our Q3 Report. This has been a period of progress for 4SC AG, as we continue to advance the development of our lead asset #resminostat (#Kinselby) which has been clinically proven to improve progression free survival in advanced-stage Cutaneous T-Cell Lymphoma (CTCL).   You can read our Q3 Report using the links in the comments below. #CTCL #CutaneousTCellLymphoma #RareDiseases #Q3Report

Tomorrow is #RareDiseaseDay2024. Rare diseases like lymphoma face significant challenges in receiving adequate awareness and resources to power the research that makes new treatments and cures possible. From the earliest stages of discovery to patient access, LRF is working to close the innovation gap by empowering the next generation of lymphoma researchers and fostering world-class collaboration: https://lnkd.in/gZiXruEH